AMGN vs BAC
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. BAC: A global leader in financial services, Bank of America provides comprehensive banking, investment, and market-making services to a vast array of individual and institutional clients.
Side-by-side fundamentals
| Metric | AMGN | BAC | Edge |
|---|---|---|---|
| Price as of 2026-08-13 close | $417.84 | $64.09 | |
| Market cap as of 2026-08-14 | $225.9B | $448.2B | |
| P/E as of 2026-08-14 | 25.73 | 13.29 | BAC lower |
| PEG as of 2026-08-14 | 5.48 | 0.92 | BAC lower |
| Net margin as of 2026-08-14 | +22.9% | +30.2% | BAC higher |
| Gross margin as of 2026-08-14 | +74.3% | n/a | |
| Operating margin as of 2026-08-14 | +30.3% | +32.7% | BAC higher |
| ROE as of 2026-08-14 | +89.3% | +11.1% | AMGN higher |
| ROA as of 2026-08-14 | +9.5% | +1.0% | AMGN higher |
| Debt / equity as of 2026-08-14 | 4.90 | 2.43 | BAC lower |
| Revenue growth (YoY) as of 2026-08-14 | +9.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +11.8% | +6.0% | AMGN higher |
| Dividend yield as of 2026-08-14 | +2.4% | +2.0% | AMGN higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-14 | 0.42 | 1.22 | |
| 1-year return as of 2026-08-13 close | +44.4% | +35.7% | AMGN higher |
Fundamentals: market data, as of 2026-08-14. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-13.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.